Kenvue Inc. News
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
see moreKenvue Inc. Market News
13d
Kenvue’s Debt Restructuring Accelerates with Third Supplemental Indenture as Exchange Offer Launches
- Kenvue (NYSE: KVUE) amended its senior notes indenture on October 9 and Kimberly‑Clark has launched consent solicitations and exchange offers this week.
27d
KVUE Gains U.S. FDA Approval for Tylenol‑Naproxen OTC Combo as Merger Progresses
Kenvue (KVUE) won FDA approval for a new OTC Tylenol‑Naproxen combination with three‑year exclusivity, bolstering Q2 results amid a pending Kimberly‑Clark deal.
24 Sep at 20:31
Kenvue Declares $0.21 Quarterly Dividend as $40 B Kimberly‑Clark Takeover Faces EU Hurdles
Kenvue (NYSE: KVUE) announced a $0.21/share quarterly dividend and is navigating EU antitrust scrutiny as Kimberly‑Clark’s proposed $40 billion acquisition faces regulatory pressure.
10 Sep at 20:31
Australia Clears Kimberly‑Clark’s $40 B Acquisition of Kenvue With Carefree, Stayfree Divestment Requirement
Australia’s competition regulator has approved Kimberly‑Clark’s $40 billion bid for Kenvue, conditional on divesting Carefree and Stayfree brands—marking a pivotal step in the merger.
27 Aug at 20:31
Kenvue Shares Dip on Q2 Margin Miss, While Institutional Stake Activity Grows
Kenvue (NYSE:KVUE) missed Q2 margin expectations as inflation and tariffs weighed, while multiple institutional investors increased stakes this week.
